Exicure, Inc. (NASDAQ:XCUR) Sees Large Drop in Short Interest

Exicure, Inc. (NASDAQ:XCUR - Get Free Report) saw a large decrease in short interest during the month of March. As of March 31st, there was short interest totalling 34,300 shares, a decrease of 23.3% from the March 15th total of 44,700 shares. Based on an average trading volume of 62,000 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.4% of the shares of the stock are short sold.

Exicure Price Performance

NASDAQ XCUR opened at $8.44 on Friday. The company has a 50 day simple moving average of $11.27 and a 200-day simple moving average of $10.91. Exicure has a 52-week low of $1.44 and a 52-week high of $36.00. The firm has a market capitalization of $53.32 million, a price-to-earnings ratio of -4.08 and a beta of 3.74.

Exicure (NASDAQ:XCUR - Get Free Report) last announced its earnings results on Tuesday, March 18th. The company reported ($3.39) EPS for the quarter.

Institutional Trading of Exicure

A hedge fund recently raised its stake in Exicure stock. Carlyle Group Inc. boosted its stake in shares of Exicure, Inc. (NASDAQ:XCUR - Free Report) by 400.0% in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 281,636 shares of the company's stock after acquiring an additional 225,308 shares during the quarter. Exicure accounts for 0.9% of Carlyle Group Inc.'s portfolio, making the stock its 11th largest position. Carlyle Group Inc. owned about 10.79% of Exicure worth $3,850,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 42.82% of the stock is owned by institutional investors and hedge funds.

Exicure Company Profile

Exicure, Inc, an early-stage biotechnology company, develops nucleic acid therapies targeting ribonucleic acid against validated targets. The company's preclinical candidate includes SCN9A that is in preclinical studies for the treatment of chronic pain. It also develops immuno-oncology therapeutics based on its proprietary SNA technology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.